Aura Biosciences, Inc. $AURA Stock Holdings Lifted by B Group Inc.

B Group Inc. lifted its holdings in Aura Biosciences, Inc. (NASDAQ:AURA) by 21.2% in the 2nd quarter, Holdings Channel.com reports. The firm owned 572,576 shares of the company’s stock after acquiring an additional 100,000 shares during the quarter. Aura Biosciences makes up about 2.8% of B Group Inc.’s holdings, making the stock its 9th largest holding. B Group Inc.’s holdings in Aura Biosciences were worth $3,584,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AURA. Long Focus Capital Management LLC raised its position in shares of Aura Biosciences by 30.8% in the 1st quarter. Long Focus Capital Management LLC now owns 3,319,582 shares of the company’s stock worth $19,453,000 after acquiring an additional 781,808 shares in the last quarter. Acorn Capital Advisors LLC purchased a new position in Aura Biosciences in the first quarter valued at about $3,460,000. Levin Capital Strategies L.P. raised its holdings in Aura Biosciences by 9.9% in the second quarter. Levin Capital Strategies L.P. now owns 1,495,560 shares of the company’s stock worth $9,362,000 after purchasing an additional 134,792 shares in the last quarter. Franklin Resources Inc. raised its holdings in Aura Biosciences by 5.9% in the second quarter. Franklin Resources Inc. now owns 2,340,810 shares of the company’s stock worth $14,653,000 after purchasing an additional 130,221 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Aura Biosciences during the first quarter valued at about $561,000. 96.75% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Los Pinos Elisabet De sold 9,049 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $6.35, for a total value of $57,461.15. Following the completion of the transaction, the insider directly owned 474,391 shares in the company, valued at $3,012,382.85. This trade represents a 1.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CTO Mark Plavsic sold 12,169 shares of Aura Biosciences stock in a transaction that occurred on Thursday, October 16th. The shares were sold at an average price of $6.35, for a total transaction of $77,273.15. Following the sale, the chief technology officer owned 197,287 shares of the company’s stock, valued at approximately $1,252,772.45. The trade was a 5.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 39,223 shares of company stock valued at $233,155. Company insiders own 6.30% of the company’s stock.

Aura Biosciences Trading Down 0.5%

NASDAQ AURA opened at $6.40 on Tuesday. Aura Biosciences, Inc. has a 12-month low of $4.34 and a 12-month high of $9.14. The company has a fifty day simple moving average of $5.93 and a two-hundred day simple moving average of $6.27. The stock has a market cap of $406.40 million, a P/E ratio of -3.30 and a beta of 0.44.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Thursday, November 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.06. As a group, sell-side analysts forecast that Aura Biosciences, Inc. will post -1.66 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AURA. Zacks Research raised shares of Aura Biosciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 19th. Evercore ISI started coverage on shares of Aura Biosciences in a report on Tuesday, November 25th. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research report on Wednesday, August 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research report on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Aura Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $20.50.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.